Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Masashi Mizuno's publication output changed over time?
ScholarIQpublication output · 2001–2023
Output declined50% over the shown period — from 2 works in 2001 to 1 in 2023.
2
1
1
1
1
1
3
1
20012005200620072009201120182023
What are the most-cited papers on Masashi Mizuno?
ScholarIQmost cited works
Scar-Associated Macrophages Are a Major Source of Hepatic Matrix Metalloproteinase-13 and Facilitate the Resolution of Murine Hepatic Fibrosis
Jonathan Fallowfield, Masashi Mizuno, Timothy J. Kendall, Christothea M. Constandinou, R. Christopher Benyon, Jeremy S. Duffield, John P. Iredale
S38008053. 2007472 Citations
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
Masashi Mizuno, Atsushi Kuno, Toshiyuki Yano, Takayuki Miki, H Oshima, Tatsuya Sato, Kei Nakata, Yukishige Kimura, Masaya Tanno, Tetsuji Miura
S91696817. 2018170 CitationsOPEN ACCESS
CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells
Kristina Elward, Mark Griffiths, Masashi Mizuno, Claire L. Harris, J. W. Neal, B. Paul Morgan, Philippe Gasque
S140251998. 2005139 CitationsOPEN ACCESS
Hip Fracture Prevention Trial Using Hip Protectors in Japanese Nursing Homes
Atsushi Harada, Masashi Mizuno, Marie Takemura, Haruhiko Tokuda, Hiroyasu Okuizumi, Naoakira Niino
S170889201. 2001133 Citations
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
H Oshima, Takayuki Miki, Atsushi Kuno, Masashi Mizuno, Tatsuya Sato, Masaya Tanno, Toshiyuki Yano, Kei Nakata, Yukishige Kimura, Koki Abe, Wataru Ohwada, Tetsuji Miura
S102125482. 2018129 CitationsOPEN ACCESS
Related on ScholarIQ
Nagoya University
Institution
Scar-Associated Macrophages Are a Major Source of Hepatic Matrix Metalloproteinase-13 and Facilitate the Resolution of Murine Hepatic Fibrosis
Paper
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
Paper
CD46 Plays a Key Role in Tailoring Innate Immune Recognition of Apoptotic and Necrotic Cells
Paper
Hip Fracture Prevention Trial Using Hip Protectors in Japanese Nursing Homes
Paper
Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats
Paper